

- **Name:** Jiun-I Lai, M.D., Ph.D.
 - **Current Position & Affiliation:** Attending Physician, Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taiwan
Associate Professor, Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
 - **Country:** Taiwan
-

- **Educational Background:**

Ph.D. in Cellular and Molecular Biology, The Scripps Research Institute, La Jolla, CA (2010–2016)

M.D., School of Medicine, National Yang-Ming University, Taipei, Taiwan (1998–2005)

- **Professional Experience:**

Associate Professor, Institute of Clinical Medicine, National Yang-Ming Chiao Tung University (2025–present)

Assistant Professor, Institute of Clinical Medicine, National Yang-Ming University (2018–2025)

Adjunct Assistant Professor, School of Medicine, National Yang-Ming University (2018–)

Oncologist, Dept. of Oncology, Taipei Veterans General Hospital (2017–present)

Internal Medicine Residency, Taipei Veterans General Hospital (2006–2009)

- **Professional Organizations:**

Vice Secretary-General, Taiwan Society of Breast Health (2023–2025)

Board-certified:

Taiwan Board of Internal Medicine (No. 8322)

Taiwan Society of Cancer Medicine – Medical Oncology (No. 1589)

Taiwan Society of Breast Cancer (No. 1265)

ECFMG Certificate, USA

- **Main Scientific Publications:**

1. Ting-I Lin, Yi-Ru Tseng, Min-Jyun Dong, Chih-Yi Lin, Wei-Ting Chung, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Ta-Chung Chao, **Jiun-I Lai**. HDAC inhibitors modulate Hippo pathway signaling in hormone-positive breast cancer. *Clinical Epigenetics* 2025 Feb 26;17(1):37.
2. **Lai JI**, Jung KH, Shimizu C, Tiambeng ML, Tseng LM, Hsu DC, Ihm SY, Spiteri C, Tan EM, Qu S, Antill Y. Patients' and doctors' preferences in early-stage triple-negative breast cancer treatment in Asia-Pacific: a multi-territory

- discrete choice experiment using a cross-sectional survey. *BMJ Open*. 2025 Mar 3;15(3):e088505
3. I-Wei Ho, Yi-Ru Tseng, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Ta-Chung Chao, **Jiun-I Lai**. Addition of bevacizumab to vinorelbine-platinum combination is efficacious in heavily pretreated HER2-negative metastatic breast cancer. *J Cancer* 2025; 16(5):1726-1735. doi:10.7150/jca.105199
 4. Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park, Rinath Jeselsohn, Miguel Martin, Rachel M Layman, Sara A Hurvitz, Sarah Sammons, Peter A Kaufman, Montserrat Muñoz, **Jiun-I Lai**, Holly Knoderer, Cynthia Sandoval, Aarti R Chawla, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lacey M Litchfield 14, Lillian Smyth, Seth A Wander. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial. *J Clin Oncol*. 2024 Dec 18; JCO2402086. doi: 10.1200/JCO-24-02086
 5. **Jiun-I Lai**, Yu-Ching Peng, Peter Mu-Hsin Chang, Yen-Hwa Chang, Hsiao-Jen Chung, Yi-Hsiu Huang, Tzu-Ping Lin, William J Huang, Tzu-Chun Wei, Tzu-Hao Huang, Chueh-Chuan Yen. Real world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma. *Journal of the Chinese Medical Association* ();10.1097/JCMA.0000000000001209, January 17, 2025.
 6. **Jiun-I Lai**, Ting-Hao Kuo, Kuan-jung Huang, Laura Min Xuan Chai, Mei-Hsuan Lee, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Cheng-Chih Hsu, Ta-Chung Chao. Clinical and genotypic insights into higher prevalence of palbociclib associated neutropenia in Asian patients. *The Oncologist*. 2024 Apr 4;29(4):e455-e466
 7. ChihYi Lin, Chung-Jen Yu, Chia-I Shen, Chun-Yu Liu, Ta-Chung Chao, Chi-Cheng Huang, Ling-Ming Tseng, **Jiun-I Lai**. IKZF3 amplification frequently occurs in HER2 positive breast cancer and is a potential therapeutic target. *Medical Oncology*, 2022 Sep 30;39(12):242. doi: 10.1007/s12032-022-01812-x.
 8. Chih-Yi Lin, Chung-Jen Yu, Chun-Yu Liu, Ta-Chung Chao, Chi-Cheng Huang, Ling-Ming Tseng, **Jiun-I Lai**. CDK4/6 inhibitors downregulate the ubiquitin conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER+ breast cancer. *Clinical and Translational Oncology* 2022 Aug 2. doi: 10.1007/s12094-022-02881-0
 9. **Lai JI**, Tseng YJ, Chen MH, Huang CF, Chang PM. Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. *Front Oncol*. 2020 Nov 16;10:561936
 10. Chang SC, Lai YC, Chang CY, Huang LK, Chen SJ, Tan KT, Yu PN, **Lai JI**. Concomitant Genetic Alterations are associated with worse clinical outcome in EGFR mutant NSCLC patients treated with tyrosine kinase inhibitors. **(Corresponding Author)** *Transl Oncol*. 2019 Aug 8;12(11):1425-1431. doi: 10.1016/j.tranon.2019.07.008.